-
BIBR 1532 Telomerase Inhibition Workflows
2026-08-21
BIBR 1532 is a selective, non-nucleosidic telomerase inhibitor for connecting hTERT suppression with cancer cell proliferation inhibition and apoptosis. This practical guide shows how to formulate, dose, validate, and troubleshoot BIBR 1532 assays while using recent telomere-attrition research to design stronger combination studies.
-
PTT and CD47 Blockade in Oral Cancer
2026-08-20
A 2026 study shows that photothermal therapy (PTT) strengthens CD47 blockade in oral squamous cell carcinoma by supplying a calreticulin-dependent phagocytic signal and improving macrophage access through extracellular matrix remodeling. The work provides a mechanistic framework for overcoming two limitations of macrophage-directed immunotherapy: insufficient tumor-cell recognition and physical exclusion within solid tumors.
-
Phalloidin B7678: F-Actin Workflow Guide
2026-08-20
Phalloidin (SKU B7678) is a cyclic heptapeptide toxin and F-actin high affinity probe for stabilizing and visualizing filamentous actin in fixed, permeabilized, tissue, and cell-free assays. It is not appropriate for live-cell imaging or experiments that require reversible actin remodeling because its binding stabilizes filaments and disrupts normal cytoskeletal dynamics.
-
Asunaprevir (BMS-650032): HCV Research Guide
2026-08-19
Asunaprevir, also known as BMS-650032, is a noncovalent HCV NS3/4A protease inhibitor with a reported biochemical IC50 of 1 nM. Its research profile includes activity across HCV genotype subtypes, inhibition of HCV RNA replication in several cell lines, oral exposure, and hepatotropic disposition.
-
AMPK Suppresses ULK1 During Energy Stress
2026-08-19
The reference study challenges the prevailing view that AMPK broadly activates autophagy during glucose starvation. Its experiments show that AMPK suppresses ULK1 initiation signaling while preserving autophagy machinery, revealing a two-part energy-stress response with important implications for interpreting autophagy assays.
-
Filipin III for Membrane Cholesterol Imaging
2026-08-18
Filipin III turns membrane cholesterol biology into a spatially testable assay, supporting cell imaging, membrane-fraction analysis, and ultrastructural validation. This workflow connects cholesterol-rich membrane microdomains with the 25-hydroxycholesterol–macrophage pathway while clearly separating cholesterol mapping from oxysterol quantification.
-
3D Cardiac Organoid Mapping with Shell MEAs
2026-08-18
Choi and colleagues introduce shape-adaptive shell microelectrode arrays that encapsulate cardiac organoids and resolve electrical activity across their three-dimensional geometry. The platform combines electrophysiological mapping, calcium imaging, and pharmacological perturbation to support longitudinal cardiac electrophysiology research and more informative arrhythmia modeling.
-
Phosphatase Inhibitor Cocktail 2: Assay Guide
2026-08-17
Protect phosphorylation-dependent signals from harvest through analysis with a broad-spectrum inhibitor workflow for lysates, immunoprecipitations, imaging, and kinase assays. This guide combines practical 1X dosing with cold handling, matched controls, and design principles from recent target-profiling research to improve assay specificity without overcomplicating sample preparation.
-
E-4031 for 3D Cardiac Electrophysiology
2026-08-17
E-4031 provides a controlled pharmacological stressor for revealing repolarization defects, conduction heterogeneity, and arrhythmogenic activity in three-dimensional cardiac organoids. When paired with shell microelectrode arrays and calcium imaging, it supports higher-content cardiac electrophysiology research than planar recordings alone.
-
Dimetridazole: From Antimicrobial Tool to Signal
2026-08-16
Dimetridazole, also known as 1,2-Dimethyl-5-nitroimidazole, is more than a conventional antimicrobial research compound. Its reported effects on microbial growth, membrane-associated pathways, quorum sensing, and biofilm formation—together with highly sensitive electrochemical detection—create a translational workflow for studying resistance, pathogenesis, combination therapy, and residue analysis.
-
Artemisinin, NRF2, and Ferroptosis in Diabetic Cognition
2026-08-15
Wang et al. show that artemisinin improves learning and memory in STZ-induced type 2 diabetes mellitus mice by activating hippocampal NRF2-associated antioxidant defenses and limiting neuronal ferroptosis. The study combines behavioral, biochemical, protein, histological, and ultrastructural evidence, while inhibitor and ferroptosis-inducer experiments strengthen the proposed NRF2–ferroptosis mechanism.
-
X-Gal Workflows for Cloning and Reporter Assays
2026-08-14
X-Gal converts lacZα complementation into a rapid visual checkpoint for molecular cloning, while also supporting qualitative β-galactosidase activity assay workflows. This guide connects reliable blue-white colony screening with practical construct validation and carefully bounded applications inspired by recent olfactory receptor research.
-
AZD3463: ALK/IGF1R Inhibitor for Neuroblastoma
2026-08-14
AZD3463 is an orally bioavailable ALK/IGF1R inhibitor for preclinical neuroblastoma research. Reported activity includes inhibition of wild-type and mutant ALK, suppression of PI3K/AKT/mTOR signaling, chemotherapy sensitization, and tumor-growth reduction in orthotopic mouse models.
-
NF 449: From P2X1 Potency to Translation
2026-08-13
NF 449 is a highly selective purinergic receptor antagonist that helps translational researchers separate P2X1-driven platelet signaling from broader purinergic effects. This thought-leadership perspective connects receptor pharmacology with assay design, antithrombotic agent research, and more disciplined decisions about translation.
-
TH287 MTH1 Inhibitor for Radiosensitization
2026-08-13
TH287 converts oxidized nucleotide stress into a controllable DNA-damage vulnerability, making it useful for mechanistic cancer assays and radiotherapy-combination studies. Its most distinctive application is schedule-sensitive radiosensitization, with early ionizing radiation after drug exposure showing strong activity in castration-resistant prostate cancer models.